Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$46.99 USD
-0.31 (-0.66%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $46.97 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Tandem Diabetes Care, Inc. [TNDM]
Reports for Purchase
Showing records 161 - 180 ( 241 total )
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Pre-Announces In Line 4Q15 And Initial 2016 Revenue Guidance; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
MedTech 2016 Outlook: Risk/Reward Looks Attractive
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Positive (Albeit Temporary) Implications of a 2-Year Suspension of the Medical Device Tax
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Impressive Q3 Results, Price Target to $14.75, Reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
The Calm Before The Storm; Expecting Sales To Significantly Accelerate in 4Q and Beyond; Reiterate
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Feltl Insulin Pump Project: Historical survey of -5,700 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Insulin Pump Project: Historical survey of ~5,700 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
T:slim G4 Receives FDA Approval; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Conference Call Takeaways Following t:slim G4 Approval; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Medical Devices - Key Takeaways from the Wedbush PacGrow Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Key Takeaways from the Wedbush PacGrow Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Q2 beats, t:flex guidance raised, pipeline on track, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Insulin Pump Project: Historical survey of ~5,500 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Rapid Adoption of Tandem''s Insulin Pump Continues Unfazed by Competition; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Medical Devices - 2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15 Remains Positive
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Q1 slightly ahead, guidance reiterated, pipeline updates, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B